The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Adominal Infections - The European Experience

References

• Blot S, De Wade JJ. Critical issues in the clinical manage-ment of complicated infra-abdominal infections. Drugs 2005; 65: 1611–1620.
   PubMed Web of Science ®Google Scholar
• Sweet RL, Bartlett JG, Hemsell DL et al. Evaluation of new anti-infective drugs for the treatment of acute pelvic inflamma-tory disease. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15, Suppl 1: S53–61.
   Google Scholar
• Solomkin J, Mazuski J, Baron Eea. Guidelines for the Se-lection of Anti-infective Agent for Complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
   PubMed Web of Science ®Google Scholar
• Woodford N, Ward ME, Kaufmann ME. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735–743.
   PubMed Web of Science ®Google Scholar
• Rossi F, Baquero F, Hsueh PR et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli iso-lated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205–210.
   Google Scholar
• Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451–454.
   PubMed Web of Science ®Google Scholar
• Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX- M extended-spectrum 13-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628–633.
   Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19–36.
   PubMed Web of Science ®Google Scholar
• Gales AC, Silva JB, Andrade SS et al. In vitro activity of the tigecycline, a new glycylcycline, tested against 1326 clinical bacterial strains isolated from the Latin American region. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 207.
   Google Scholar
• Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and com-parative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595–2601.
   Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimi-crob Agents Chemother 1999; 43, 738-744.
   Google Scholar
• Bush K, Macielag M. New approaches in the treatment of bacterial infections. Curr Opin Chem Biol 2000; 4: 433–439.
   PubMed Web of Science ®Google Scholar
• Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: Getting it right the first time. Drugs 2003; 63: 2157–2168.
   PubMed Web of Science ®Google Scholar
• Meehan TP, Fine MJ, Krumholz HM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–2084.
   PubMed Web of Science ®Google Scholar
• Mylotte JM, Graham R, Kahler L et al. Epidemiology of nosocomial infection and resistant organisms in patients admit-ted for the first time to an acute rehabilitation unit. Clin Infect Dis 2000; 30: 425–432.
   Google Scholar
• Shlaes DM, Gerding DN, John JFJ. Society for Health-care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Re-sistance: Guidelines for the Prevention of Antimicrobial Resist-ance in Hospitals. Clin Infect Dis 1997; 25: 584–599.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Carmeli Y. The impact of antimicrobial re-sistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433–1437.
   PubMed Web of Science ®Google Scholar
• Hurr H, Hawley HB, Czachor JS et al. APACHE II and ISS scores as predictors of nosocomial infections in trauma pa-tients. Am J Infect Contr 1999; 27: 79–83.
   Google Scholar
• McCusker ME, Perisse AR, Roghmann MC. Severity-of-illness markers as predictors of nosocomial infection in adult in-tensive care unit patients. Am J Infect Control 2002; 30: 139–144.
   PubMed Web of Science ®Google Scholar
• Craven DE, Kunches LM, Lichtenberg DA et al. Nosoco-mial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med 1988; 148: 1161–1168.
   Google Scholar
• Cunnion KM, Weber DJ, Broadhead WE et al. Risk factors for nosocomial pneumonia: comparing adult critical-care popu-lations. Am J Respir Crit Care Med 1996; 153: 158–162.
   PubMed Web of Science ®Google Scholar
• Mazuski J, Sawyer R, Nathens Aea. The Surgical Infec-tion Society Guidelines on Antimicrobial Therapy for Intra-Ab-dominal Infections: An Executive Summary. Surg Infect 2002; 3: 161–173.
   PubMedGoogle Scholar
• Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
   Google Scholar
• Fomin P, Beuran M, Gradauskas A et al. Tigecycline is ef-ficacious in the treatment of complicated intra-abdominal infec-tions. Int J Surg 2005; 3: 35–47.
   Google Scholar
• Biedenbach DJ, Beach ML, Jones RN. In vitro antimi-crobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains produc-ing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173–177.
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Gatward T, Warner M et al. Antibiotic re-sistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479–487.
   Google Scholar
• Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired infra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682–687.
   Google Scholar
• Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent Euro-pean clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400–404.
   Google Scholar
• Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31: 2228–2237.
   PubMed Web of Science ®Google Scholar
• Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007; 8: 2933–2945.
   PubMed Web of Science ®Google Scholar
• Laterre PF, Colardyn F, Delmee M et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the In-fectious Disease Advisory Board (IDAB). Acta Chir Belg 2006; 106: 2–21.
   Google Scholar